Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
letter
. 2020 Aug 3;123(9):1467. doi: 10.1038/s41416-020-1013-5

Comment on: ‘Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients’

Margot De Marco 1, Alessandra Rosati 1, Maria Caterina Turco 1,, Liberato Marzullo 1
PMCID: PMC7591487  PMID: 32741973

In their recent article on biomarker-based risk of pancreatic cancer,1 the authors analyse the potential value of Trefoil protein 1 (TFF1) as a component of a PancRISK panel. Our group has been long involved in studying pancreatic cancer.2,3 This paper particularly attracted our attention, because some members of our group have previous experience in the study of TFF1.4,5 In particular, we showed that copper binding, promoting the TFF1 homodimerisation, increased its motogenic activity in in vitro wound-healing assays.4 That finding appeared to suggest a possible activity of TFF1 on cancer cell motility.

In the same period of the publication of the article by Blyuss et al.,1 another article reported the anticancer activity of some copper complexes in pancreatic cancer cells.6 Due to the role of copper in TFF1 activity, we might speculate that the anticancer effect of copper complexes in pancreatic cancer can be due to a possible interference of the complexes with the correct TFF1–copper interaction.

We believe that these different pieces of evidence concur in supporting a role for TFF1 in pancreatic cancer, and that this topic can be worthy of further studies.

Author contributions

Writing—original draft preparation: M.C.T.; writing—review and editing: M.D.M., A.R. and L.M.

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

Data availability

Not applicable.

Competing interests

The authors declare no competing interests.

Funding information

None.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Blyuss O, Zaikin A, Cherepanova V, Munblit D, Kiseleva EM, Prytomanova OM, et al. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. Br. J. Cancer. 2020;122:692–696. doi: 10.1038/s41416-019-0694-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Rosati A, Basile A, D’Auria R, d’Avenia M, De Marco M, Marzullo L, et al. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nat. Commun. 2015;6:8695. doi: 10.1038/ncomms9695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Iorio V, Rosati A, D’Auria R, De Marco M, Marzullo L, Basile A, et al. Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8+ T cell number and tumour growth in pancreatic cancer. Gut. 2018;67:780–782. doi: 10.1136/gutjnl-2017-314225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Tosco A, Monti MC, Fontanella B, Montefusco S, D’Andrea L, Ziaco B, et al. Copper binds the carboxy-terminus of trefoil protein 1 (TFF1), favoring its homodimerization and motogenic activity. Cell Mol. Life Sci. 2010;67:1943–1955. doi: 10.1007/s00018-010-0309-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Montefusco S, Esposito R, D’Andrea L, Monti MC, Dunne C, Dolan B, et al. Copper promotes TFF1-mediated Helicobacter pylori colonization. PLoS ONE. 2013;8:e79455. doi: 10.1371/journal.pone.0079455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Carcelli M, Tegoni M, Bartoli J, Marzano C, Pelosi G, Salvalaio M, et al. In vitro and in vivo anticancer activity of tridentate thiosemicarbazone copper complexes: unravelling an unexplored pharmacological target. Eur. J. Med. Chem. 2020;194:112266. doi: 10.1016/j.ejmech.2020.112266. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Not applicable.


Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES